The US Food and Drug Administration (FDA) has approved Novo Nordisk’s diabetes-cum-weight loss drug Ozempic for patients with both chronic kidney disease (CKD) and diabetes after clinical trials ...

It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news ...

AS DEMAND GOES UP.. BUT HE SA Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the U.S. Food and Drug Administration to reduce ...